Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review)
Open Access
- 17 June 2013
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 6 (2) , 295-305
Abstract
Current endocrine therapies for females with estrogen receptor‑positive breast cancer have facilitated substantial improvements in outcomes. The effectiveness of endocrine therapy is limited by either initial de novo resistance or acquired endocrine resistance. Multiple mechanisms responsible for endocrine resistance have been proposed, including deregulation of various components of the estrogen receptor (ER) pathway, alterations in cell cycle and cell survival signaling molecules, and the activation of escape pathways. Dysregulation of miRNA expression has been associated with experimental and clinical endocrine therapy resistance. miRNAs are pivotal to understanding the complex biological mechanism of endocrine resistance, and may serve as novel candidate predictive and prognostic surrogates and therapeutic targets. This review focuses on current progress concerning the roles of miRNAs in endocrine resistance, and discusses the challenges and opportunities for implementing miRNA‑based assays and treatment for patients with endocrine‑resistant breast cancer.Keywords
This publication has 78 references indexed in Scilit:
- Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cellsCancer Letters, 2011
- High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancerBreast Cancer Research and Treatment, 2011
- The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cellsBreast Cancer Research and Treatment, 2010
- Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesCell Research, 2008
- Silencing of microRNAs in vivo with ‘antagomirs’Nature, 2005
- MicroRNA expression profiles classify human cancersNature, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA TargetsCell, 2005
- The functions of animal microRNAsNature, 2004
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002